Cargando…

Randomized Clinical Trial of Antibiotic Therapy for Antenatal Pyelonephritis

Objective: The aim of this study was to prospectively evaluate the efficacy of a therapeutic course of intravenous antibiotics followed by oral antibiotics vs. intravenous antibiotics alone to prevent recurrent urinary tract infection. Methods: Pyelonephritis was documented by strict criteria in 67...

Descripción completa

Detalles Bibliográficos
Autores principales: Brost, Brian C., Campbell, Barry, Stramm, Sue, Eller, Daniel, Newman, Roger B.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364502/
https://www.ncbi.nlm.nih.gov/pubmed/18476110
http://dx.doi.org/10.1155/S1064744996000567
_version_ 1782153969585356800
author Brost, Brian C.
Campbell, Barry
Stramm, Sue
Eller, Daniel
Newman, Roger B.
author_facet Brost, Brian C.
Campbell, Barry
Stramm, Sue
Eller, Daniel
Newman, Roger B.
author_sort Brost, Brian C.
collection PubMed
description Objective: The aim of this study was to prospectively evaluate the efficacy of a therapeutic course of intravenous antibiotics followed by oral antibiotics vs. intravenous antibiotics alone to prevent recurrent urinary tract infection. Methods: Pyelonephritis was documented by strict criteria in 67 pregnant women who were then treated with appropriate intravenous antibiotics until afebrile and asymptomatic for 48 h. Women were then randomized to completion of a 10-day course of oral nitrofurantoin 100 mg qid or no further antibiotic therapy. Urine cultures (UC) were obtained 2 and 6 weeks after discharge, and at delivery. A positive UC or readmission for pyelonephritis was considered endpoints for participation in the study. Antibiotic suppression was not used. Results: Readmission for pyelonephritis prior to the 2-week follow-up visit occurred in 2/36 (5.6%) women randomized to the oral therapy group compared to 4/31 (12.9%) in the no oral treatment group (P = 0.29). At the 2-week follow-up visit, 6/31 (19.4%) women had a positive UC in the oral therapy compared to 8/26 (30.1%) in the no oral treatment group but this difference was not statistically significant (P = 0.31). Conclusions: Completion of 10 days of antibiotic therapy with oral medication does not significantly reduce the risk of recurrent pyelonephritis immediately post-parenteral treatment. Women in the no oral treatment group had a non-significant increase in positive UC at the 2-week follow-up visit. The high rates of recurrent urinary tract infection during pregnancy in both groups underscore the need for regular UC and for the possible role of oral antibiotic suppression.
format Text
id pubmed-2364502
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-23645022008-05-12 Randomized Clinical Trial of Antibiotic Therapy for Antenatal Pyelonephritis Brost, Brian C. Campbell, Barry Stramm, Sue Eller, Daniel Newman, Roger B. Infect Dis Obstet Gynecol Research Article Objective: The aim of this study was to prospectively evaluate the efficacy of a therapeutic course of intravenous antibiotics followed by oral antibiotics vs. intravenous antibiotics alone to prevent recurrent urinary tract infection. Methods: Pyelonephritis was documented by strict criteria in 67 pregnant women who were then treated with appropriate intravenous antibiotics until afebrile and asymptomatic for 48 h. Women were then randomized to completion of a 10-day course of oral nitrofurantoin 100 mg qid or no further antibiotic therapy. Urine cultures (UC) were obtained 2 and 6 weeks after discharge, and at delivery. A positive UC or readmission for pyelonephritis was considered endpoints for participation in the study. Antibiotic suppression was not used. Results: Readmission for pyelonephritis prior to the 2-week follow-up visit occurred in 2/36 (5.6%) women randomized to the oral therapy group compared to 4/31 (12.9%) in the no oral treatment group (P = 0.29). At the 2-week follow-up visit, 6/31 (19.4%) women had a positive UC in the oral therapy compared to 8/26 (30.1%) in the no oral treatment group but this difference was not statistically significant (P = 0.31). Conclusions: Completion of 10 days of antibiotic therapy with oral medication does not significantly reduce the risk of recurrent pyelonephritis immediately post-parenteral treatment. Women in the no oral treatment group had a non-significant increase in positive UC at the 2-week follow-up visit. The high rates of recurrent urinary tract infection during pregnancy in both groups underscore the need for regular UC and for the possible role of oral antibiotic suppression. Hindawi Publishing Corporation 1996 /pmc/articles/PMC2364502/ /pubmed/18476110 http://dx.doi.org/10.1155/S1064744996000567 Text en Copyright © 1996 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Brost, Brian C.
Campbell, Barry
Stramm, Sue
Eller, Daniel
Newman, Roger B.
Randomized Clinical Trial of Antibiotic Therapy for Antenatal Pyelonephritis
title Randomized Clinical Trial of Antibiotic Therapy for Antenatal Pyelonephritis
title_full Randomized Clinical Trial of Antibiotic Therapy for Antenatal Pyelonephritis
title_fullStr Randomized Clinical Trial of Antibiotic Therapy for Antenatal Pyelonephritis
title_full_unstemmed Randomized Clinical Trial of Antibiotic Therapy for Antenatal Pyelonephritis
title_short Randomized Clinical Trial of Antibiotic Therapy for Antenatal Pyelonephritis
title_sort randomized clinical trial of antibiotic therapy for antenatal pyelonephritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364502/
https://www.ncbi.nlm.nih.gov/pubmed/18476110
http://dx.doi.org/10.1155/S1064744996000567
work_keys_str_mv AT brostbrianc randomizedclinicaltrialofantibiotictherapyforantenatalpyelonephritis
AT campbellbarry randomizedclinicaltrialofantibiotictherapyforantenatalpyelonephritis
AT strammsue randomizedclinicaltrialofantibiotictherapyforantenatalpyelonephritis
AT ellerdaniel randomizedclinicaltrialofantibiotictherapyforantenatalpyelonephritis
AT newmanrogerb randomizedclinicaltrialofantibiotictherapyforantenatalpyelonephritis